GNLX · Insider Trading
Genelux Corporation Common Stock
Every open-market purchase and sale reported by GNLX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Yong Yu | Chief Scientific Officer | Sell | −9,683 | −$26.66K |
| 2026-09-02 | Thomas Zindrick | President and CEO | Sell | −34,463 | −$91.90K |
| 2026-09-02 | Joseph Cappello | Chief Technical Officer | Sell | −10,257 | −$28.11K |
| 2026-08-04 | Yong Yu | Chief Scientific Officer | Sell | −653 | −$1.92K |
| 2026-08-04 | Thomas Zindrick | President and CEO | Sell | −3,023 | −$8.91K |
| 2026-08-04 | Joseph Cappello | Chief Technical Officer | Sell | −653 | −$1.92K |
| 2026-07-02 | John W Smither | Director | Sell | −12,000 | −$34.90K |
| 2026-06-18 | Thomas Zindrick | President and CEO | A | +730,601 | — |
| 2026-06-18 | John Thomas | Director | A | +28,409 | — |
| 2026-06-18 | Eric Groen | General Counsel | A | +233,957 | — |
| 2026-06-18 | Matthew Pulisic | Chief Financial Officer | A | +278,906 | — |
| 2026-06-18 | Joseph Cappello | Chief Technical Officer | A | +174,841 | — |
| 2026-06-18 | James L Tyree | Director | A | +28,409 | — |
| 2026-06-18 | Mary Mirabelli | Director | A | +28,409 | — |
| 2026-06-18 | Yong Yu | Chief Scientific Officer | A | +119,318 | — |
| 2026-06-18 | John W Smither | Director | A | +28,409 | — |
| 2026-06-04 | Ralph Smalling | Head of Regulatory | Sell | −192 | −$563 |
| 2026-06-02 | John Thomas | Director | Sell | −10,000 | −$29.80K |
| 2026-05-12 | Ralph Smalling | Head of Regulatory | Sell | −270 | −$804 |
| 2026-05-12 | Yong Yu | Chief Scientific Officer | Sell | −605 | −$1.80K |
| 2026-05-12 | Thomas Zindrick | President and CEO | Sell | −2,798 | −$8.23K |
| 2026-05-12 | Joseph Cappello | Chief Technical Officer | Sell | −605 | −$1.80K |
| 2026-03-26 | Yong Yu | SVP, Clinical Development | Sell | −906 | −$2.19K |
| 2026-03-26 | Thomas Zindrick | President and CEO | Sell | −3,582 | −$8.67K |
| 2026-03-26 | Ralph Smalling | Head of Regulatory | Sell | −585 | −$1.44K |
| 2026-03-26 | Joseph Cappello | Chief Technical Officer | Sell | −906 | −$2.19K |
| 2026-03-03 | John Thomas | Director | Sell | −10,000 | −$28.96K |
| 2026-01-07 | Jason Litten | Chief Medical Officer | A | +275,000 deriv. | — |
| 2025-12-11 | Thomas Zindrick | President and CEO | Sell | −17,182 | −$66.37K |
| 2025-12-11 | Joseph Cappello | Chief Technical Officer | Sell | −3,706 | −$14.36K |
| 2025-12-11 | Yong Yu | SVP, Clinical Development | Sell | −4,192 | −$16.03K |
| 2025-12-09 | Ralph Smalling | Head of Regulatory | Sell | −2,332 | −$8.74K |
| 2025-12-02 | John Thomas | Director | Sell | −10,000 | −$50.01K |
| 2025-09-03 | Yong Yu | SVP, Clinical Development | MIXED | — | — |
| 2025-09-03 | Joseph Cappello | Chief Technical Officer | MIXED | — | — |
| 2025-09-03 | Ralph Smalling | Head of Regulatory | A | +10,000 | — |
| 2025-09-03 | Thomas Zindrick | President and CEO | MIXED | — | — |
| 2025-08-29 | James L Tyree | Director | A | +22,283 | — |
| 2025-08-29 | Thomas Zindrick | President and CEO | A | +361,200 | — |
| 2025-08-29 | Joseph Cappello | Chief Technical Officer | A | +107,500 | — |
| 2025-08-29 | Yong Yu | SVP, Clinical Development | A | +101,480 | — |
| 2025-08-29 | John Thomas | Director | A | +22,283 | — |
| 2025-08-29 | John W Smither | Director | A | +22,283 | — |
| 2025-08-29 | Mary Mirabelli | Director | A | +22,283 | — |
| 2025-08-29 | Ralph Smalling | Head of Regulatory | A | +26,230 | — |
| 2025-07-02 | Eric Groen | General Counsel & Secretary | A | +270,000 deriv. | — |
| 2025-06-24 | John Thomas | Director | G | −25,000 | — |
| 2025-05-13 | Ralph Smalling | Head of Regulatory | Sell | −1,259 | −$3.68K |
| 2025-05-13 | Yong Yu | VP, Clinical Trial Operations | Sell | −5,579 | −$16.29K |
| 2025-05-13 | Thomas Zindrick | President and CEO | Sell | −10,764 | −$31.43K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Thomas Zindrick | President and CEO | 1,426,427 | $2.91M |
| John Thomas | Director | 501,193 | $1.02M |
| Joseph Cappello | Chief Technical Officer | 318,480 | $649.70K |
| Matthew Pulisic | Chief Financial Officer | 278,906 | $568.97K |
| Yong Yu | Chief Scientific Officer | 258,688 | $527.72K |
| Eric Groen | General Counsel | 233,957 | $477.27K |
| Mary Mirabelli | Director | 102,693 | $209.49K |
| James L Tyree | Director | 96,483 | $196.83K |
| John W Smither | Director | 91,403 | $186.46K |
| Lourie S. Zak | Chief Financial Officer | 82,452 | $168.20K |
| Ralph Smalling | Head of Regulatory | 67,611 | $137.93K |
| Sean Ryder | General Counsel | 47,621 | $97.15K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GNLX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.